KR20200131603A - Feed composition for immunity comprising extract from yeast, food composition for immunity comprising extract from yeast and manufactuaring method for extract from yeast using ultrasonics wave - Google Patents
Feed composition for immunity comprising extract from yeast, food composition for immunity comprising extract from yeast and manufactuaring method for extract from yeast using ultrasonics wave Download PDFInfo
- Publication number
- KR20200131603A KR20200131603A KR1020190056423A KR20190056423A KR20200131603A KR 20200131603 A KR20200131603 A KR 20200131603A KR 1020190056423 A KR1020190056423 A KR 1020190056423A KR 20190056423 A KR20190056423 A KR 20190056423A KR 20200131603 A KR20200131603 A KR 20200131603A
- Authority
- KR
- South Korea
- Prior art keywords
- yeast
- extract
- ultrasonic
- present
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 41
- 239000000284 extract Substances 0.000 title claims abstract description 36
- 235000013305 food Nutrition 0.000 title claims description 27
- 238000000034 method Methods 0.000 title claims description 19
- 230000036039 immunity Effects 0.000 title abstract description 19
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 38
- 230000002708 enhancing effect Effects 0.000 claims abstract description 26
- 230000036737 immune function Effects 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 79
- 229940041514 candida albicans extract Drugs 0.000 claims description 24
- 239000012138 yeast extract Substances 0.000 claims description 24
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 17
- 229920002498 Beta-glucan Polymers 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 238000009210 therapy by ultrasound Methods 0.000 claims description 9
- 235000009508 confectionery Nutrition 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 5
- 238000005728 strengthening Methods 0.000 claims description 5
- 235000019219 chocolate Nutrition 0.000 claims description 4
- 235000012149 noodles Nutrition 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013334 alcoholic beverage Nutrition 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 235000015243 ice cream Nutrition 0.000 claims description 3
- 235000013372 meat Nutrition 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 235000013550 pizza Nutrition 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 231100001083 no cytotoxicity Toxicity 0.000 abstract description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 13
- 230000036541 health Effects 0.000 description 12
- 235000013376 functional food Nutrition 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000013355 food flavoring agent Nutrition 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000002137 ultrasound extraction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- -1 etc. Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 238000006595 Griess deamination reaction Methods 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- MZNYWPRCVDMOJG-UHFFFAOYSA-N N-(1-naphthyl)ethylenediamine dihydrochloride Chemical compound [Cl-].[Cl-].C1=CC=C2C([NH2+]CC[NH3+])=CC=CC2=C1 MZNYWPRCVDMOJG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001428754 Rat leukemia virus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/48—Ultrasonic treatment
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 효모 초음파 추출물을 함유하는 면역기능강화용 사료 조성물, 식품 조성물 및 효모 초음파 추출물의 제조 방법에 관한 것이다. The present invention relates to a feed composition for enhancing immune function, a food composition, and a method for preparing an ultrasonic yeast extract containing an ultrasonic yeast extract.
감염 및 질병은 신체의 면역기능이 저하된 상황에서 빈번히 발생하는데, 면역기능을 회복하기 위한 여러 가지 방법 중 약물복용을 통한 직접적인 방법보다는 식생활이나 천연물을 통한 간접적인 면역기능의 회복에 관한 방법이 선호되며, 이러한 요구에 부응하기 위하여 천연물 중에 존재하는 성분들의 기능성 연구에 대한 관심이 높아져가고 있다. Infections and diseases frequently occur in situations in which the body's immune function is deteriorated. Among various methods for recovering immune function, the method of indirect immune function recovery through diet or natural products is preferred to the direct method through drug administration. And, in order to meet these demands, interest in functional studies of ingredients present in natural products is increasing.
한편, 대식세포(Macrophage)는 내재면역뿐만 아니라 적응면역 등 다양한 숙주반응에 관여하여 숙주방어와 항상성 유지에 관여하는 것으로 알려져 있으며, 면역반응시에 interleukine-1β(IL-1β), interleukine-6(IL-6) 및 tumor necrosis factor (TNF)와 같은 사이토카인 (cytokines)을 생산하여 감염 초기에 생체방어에 중요한 역할을 하는 세포로 알려져 있다. 대식세포가 물질에 대응할 때 분비되는 산화질소 (nitric oxide: NO)의 생산은 면역증강에 효과가 있는 신호로 보고되고 있다.On the other hand, macrophages are known to be involved in host defense and homeostasis by engaging in various host reactions such as adaptive immunity as well as intrinsic immunity, and interleukine-1β(IL-1β), interleukine-6( IL-6) and tumor necrosis factor (TNF) by producing cytokines (cytokines) are known as cells that play an important role in bioprotection in the early stages of infection. The production of nitric oxide (NO), which is secreted when macrophages respond to substances, has been reported as an effective signal for enhancing immunity.
이에 본 발명자들은 특정한 조건에서 초음파 추출한 효모의 NO 생성량 측정을 통해 면역증강 개선 효능을 확인하고, 이를 이용한 면역기능강화용 소재로의 개발 가능성을 확인하였다.Accordingly, the present inventors confirmed the efficacy of improving immunity by measuring the amount of NO produced by ultrasonically extracted yeast under specific conditions, and confirmed the possibility of development as a material for enhancing immunity using the same.
본 발명자들은 특정 조건에서 추출한 효모 초음파 추출물을 Raw 264.7 세포에 처리한 결과 세포독성 없이 NO 생성량이 증가함을 최초로 확인하였다. 이에 본 발명의 목적은 효모 초음파 추출물의 면역 증진 효능을 최초로 검증하여 면역기능강화용 소재로써의 새로운 가치를 제시하는데 있다. The present inventors first confirmed that the amount of NO production increased without cytotoxicity as a result of treating the ultrasonic yeast extract extracted under specific conditions on Raw 264.7 cells. Accordingly, an object of the present invention is to present a new value as a material for enhancing immune function by first verifying the immunity enhancing efficacy of the yeast ultrasonic extract.
상기와 같은 본 발명의 목적을 달성하기 위해서, 본 발명의 면역기능강화용 사료 조성물은 효모(Saccharomyces cerevisiae) 초음파 추출물을 유효 성분으로 함유한다.In order to achieve the object of the present invention as described above, the feed composition for enhancing immune function of the present invention contains yeast ( Saccharomyces cerevisiae ) ultrasonic extract as an active ingredient.
본 발명의 일 실시예에 있어서, 상기 효모 초음파 추출물은 수산화나트륨(NaOH) 수용액을 용매로 이용하여 수득된 것을 특징으로 한다.In an embodiment of the present invention, the ultrasonic yeast extract is characterized in that it is obtained by using an aqueous sodium hydroxide (NaOH) solution as a solvent.
본 발명의 일 실시예에 있어서, 상기 효모 초음파 추출물은 0.1 M 내지 0.5 M의 수산화나트륨 수용액을 이용하여 10 ℃ 내지 100 ℃에서 0.5 시간 내지 7 시간 동안 10 kHz 내지 30 kHz의 주파수의 조건으로 초음파 처리하여 수득한 것을 특징으로 한다.In an embodiment of the present invention, the yeast ultrasonic extract is ultrasonicated at a frequency of 10 kHz to 30 kHz for 0.5 to 7 hours at 10° C. to 100° C. using 0.1 M to 0.5 M sodium hydroxide aqueous solution. It is characterized in that obtained by.
본 발명의 일 실시예에 있어서, 상기 효모 초음파 추출물은 1 % 내지 20 %의 베타글루칸(β-glucan)을 함유하는 것을 특징으로 한다.In one embodiment of the present invention, the ultrasonic yeast extract is characterized in that it contains 1% to 20% of beta-glucan (β-glucan).
본 발명의 면역기능강화용 식품 조성물은 효모(Saccharomyces cerevisiae) 초음파 추출물을 유효 성분으로 함유한다.The food composition for enhancing immune function of the present invention is yeast ( Saccharomyces cerevisiae ) contains ultrasonic extract as an active ingredient.
본 발명의 일 실시예에 있어서, 상기 식품은 음료류, 육류, 초코렛, 식품류, 과자류, 피자, 라면, 기타 면류, 껌류, 사탕류, 아이스크림류, 알코올 음료류, 비타민 복합제 및 건강보조식품류로 이루어진 군으로부터 선택되는 것을 특징으로 한다.In one embodiment of the present invention, the food is selected from the group consisting of beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements. It is characterized by being.
본 발명의 효모 초음파 추출물의 제조 방법은, a) 효모(Saccharomyces cerevisiae)에 수산화나트륨(NaOH) 수용액을 첨가한 후 초음파를 처리하는 단계; 및 b) 상기 a) 단계를 거친 용액을 중화하는 단계를 포함한다.The method for preparing the ultrasonic yeast extract of the present invention is a) yeast ( Saccharomyces cerevisiae ) adding an aqueous solution of sodium hydroxide (NaOH), followed by ultrasonic treatment; And b) neutralizing the solution passed through the step a).
본 발명의 일 실시예에 있어서, 상기 a) 단계는 효모를 0.1 M 내지 0.5 M의 수산화나트륨 수용액에 침지시키고, 10 ℃ 내지 100 ℃에서 0.5 시간 내지 7 시간 동안 10 kHz 내지 30 kHz의 주파수의 조건으로 초음파 처리하는 것을 특징으로 한다.In an embodiment of the present invention, in step a), the yeast is immersed in an aqueous solution of 0.1 M to 0.5 M sodium hydroxide, and a frequency of 10 kHz to 30 kHz for 0.5 to 7 hours at 10° C. to 100° C. It characterized in that the ultrasonic treatment.
본 발명에 따른 효모 초음파 추출물은 세포 독성이 없고, NO 생성을 촉진시키는 등 면역을 증강시키는 효과가 우수하다. 따라서, 본 발명에 따른 효모 초음파 추출물은, 면역기능 강화용 식품 조성물 뿐만 아니라 사료 조성물로써 유용하게 사용될 수 있다. 또한, 면역기능 강화용 건강식품, 및 면역기능 저하로 기인하는 질환의 예방 및 치료제로 이용하는데 유용하다.The ultrasonic yeast extract according to the present invention has no cytotoxicity and has excellent effects of enhancing immunity such as promoting NO production. Therefore, the ultrasonic yeast extract according to the present invention can be usefully used as a feed composition as well as a food composition for enhancing immune function. In addition, it is useful as a health food for strengthening immune function, and for preventing and treating diseases caused by decreased immune function.
도 1은 실시예 및 비교예들의 NO 생성량 측정 결과이다.
도 2는 실시예 및 비교예들의 세포 독성을 측정한 결과이다. 1 is a result of measuring the amount of NO produced in Examples and Comparative Examples.
2 is a result of measuring the cytotoxicity of Examples and Comparative Examples.
이하, 본 문서의 다양한 실시예들이 첨부된 도면을 참조하여 기재된다. 실시예 및 이에 사용된 용어들은 본 문서에 기재된 기술을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 해당 실시예의 다양한 변경, 균등물, 및/또는 대체물을 포함하는 것으로 이해되어야 한다. Hereinafter, various embodiments of the present document will be described with reference to the accompanying drawings. The examples and terms used therein are not intended to limit the technology described in this document to a specific embodiment, and should be understood to include various modifications, equivalents, and/or substitutes of the corresponding embodiments.
이하, 첨부한 도면을 참조하여 본 발명의 실시예를 상세하게 설명하면 다음과 같다.Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings.
본 발명은 효모(Saccharomyces cerevisiae) 초음파 추출물을 유효 성분으로 함유하는 면역기능강화용 사료 조성물 또는 식품 조성물에 관한 것이다. 자세하게, 본 발명은 1 % 내지 20 %의 베타글루칸(β-glucan)을 함유하는 효모 초음파 추출물을 유효 성분으로 함유하는 면역기능강화용 사료 조성물 또는 식품 조성물에 관한 것이다. 바람직하게. 본 발명의 효모 초음파 추출물은 6 % 내지 11 %의 베타글루칸을 함유할 수 있다.The present invention is yeast ( Saccharomyces cerevisiae ) It relates to a feed composition or food composition for enhancing immune function containing an ultrasonic extract as an active ingredient. In detail, the present invention relates to a feed composition or a food composition for strengthening immune function containing an ultrasonic yeast extract containing 1% to 20% of beta-glucan as an active ingredient. Preferably. The ultrasonic yeast extract of the present invention may contain 6% to 11% of beta glucan.
본 발명의 효모 초음파 추출물은, 수산화나트륨(NaOH) 수용액을 용매로 이용한 초음파 추출을 통해 수득될 수 있다. 구체적으로, 효모 초음파 추출물은 0.1 M 내지 0.5 M의 수산화나트륨 수용액을 이용하여 10 ℃ 내지 100 ℃에서 0.5 시간 내지 7 시간 동안 10 kHz 내지 30 kHz의 주파수의 조건으로 초음파 처리하여 수득될 수 있다. 바람직하게는, 효모 초음파 추출물은 0.25 M 내지 0.5 M의 수산화나트륨 수용액을 이용하여 90 ℃에서 1 시간 내지 5 시간 동안 20 kHz의 주파수의 조건으로 초음파 처리하여 수득될 수 있다. 한편, 80 %의 진폭, 750 W, 펄스(pulse) 20s on/10s off의 조건에서 진행될 수 있다. The ultrasonic yeast extract of the present invention may be obtained through ultrasonic extraction using an aqueous sodium hydroxide (NaOH) solution as a solvent. Specifically, the yeast ultrasonic extract may be obtained by ultrasonic treatment at a frequency of 10 kHz to 30 kHz at 10° C. to 100° C. for 0.5 to 7 hours using 0.1 M to 0.5 M sodium hydroxide aqueous solution. Preferably, the yeast ultrasonic extract can be obtained by ultrasonic treatment at 90° C. for 1 to 5 hours at a frequency of 20 kHz using an aqueous solution of 0.25 M to 0.5 M sodium hydroxide. On the other hand, it can proceed under the conditions of 80% amplitude, 750 W, and pulse 20s on/10s off.
본 발명의 일실시예에 있어서, 효모 초음파 추출물은 사료 조성물 또는 식품 조성물 총 중량에 대하여 0.001 ~ 99중량%로 포함될 수 있다.In one embodiment of the present invention, the ultrasonic yeast extract may be included in an amount of 0.001 to 99% by weight based on the total weight of the feed composition or food composition.
본 발명의 면역기능강화용 사료 조성물 또는 식품 조성물은 본 발명의 효모 초음파 추출물을 함유하는 것 외에 통상의 사료 조성물과 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. In addition to containing the ultrasonic yeast extract of the present invention, the feed composition or food composition for enhancing immune function of the present invention may contain various flavoring agents or natural carbohydrates as an additional component, like a conventional feed composition.
상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 향미제는 천연 향미제 (타우마틴), 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제 (사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. Examples of the above-described natural carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, and the like; And polysaccharides, for example, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. The above-described flavoring agents can be advantageously used as natural flavoring agents (taumatin), stevia extracts (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.).
또한 본 발명의 사료 조성물 또는 식품 조성물은 본 발명의 효모 초음파 추출물 이외에 추가로 식품학적으로 허용 가능하거나 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 사료 조성물 또는 식품 조성물로 바람직하게 제제화할 수 있다.In addition, the feed composition or food composition of the present invention may be preferably formulated as a feed composition or a food composition, including at least one food pharmaceutically acceptable or pharmaceutically acceptable carrier in addition to the yeast ultrasonic extract of the present invention.
상기 사료 조성물 또는 식품 조성물의 제제 형태는 정제, 캡슐제, 분말, 과립, 액상, 환, 액제, 시럽, 즙, 현탁제, 유제, 또는 점적제 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효 성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다. 액상 용액으로 제제화되는 조성물에 있어서 허용 가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. Formulations of the feed composition or food composition may be tablets, capsules, powders, granules, liquids, pills, solutions, syrups, juices, suspensions, emulsions, or drops. For example, for formulation in the form of tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. In addition, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture. Suitable binders are, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, lacquercanth or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like. As acceptable pharmaceutical carriers for compositions formulated as liquid solutions, sterilization and biocompatible, saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as necessary. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to prepare injectable formulations such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or tablets.
상기와 같은 방식으로 제제화된 본 발명의 사료 조성물은 기능성 사료로 이용하거나, 각종 사료에 첨가될 수 있다. The feed composition of the present invention formulated in the above manner may be used as a functional feed or may be added to various feeds.
또한, 상기와 같은 방식으로 제제화된 본 발명의 식품 조성물은 기능성 식품으로 이용하거나, 각종 식품에 첨가될 수 있다. In addition, the food composition of the present invention formulated in the manner described above may be used as a functional food or added to various foods.
본 발명의 조성물을 첨가할 수 있는 식품으로는 음료류, 육류, 초코렛, 식품류, 과자류, 피자, 라면, 기타 면류, 껌류, 사탕류, 아이스크림류, 알코올 음료류, 비타민 복합제 및 건강보조식품류로 이루어진 군으로부터 선택되는 어느 하나에 이용될 수 있다. Foods to which the composition of the present invention can be added are selected from the group consisting of beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplements. It can be used for either
상기 사료 조성물 또는 식품 조성물은 효모 초음파 추출물 이외에 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 사료 조성물또는 식품 조성물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. The feed composition or food composition includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring and natural flavoring agents, coloring agents and heavy weight agents (cheese, chocolate, etc.), pectic acid and salts thereof in addition to the yeast ultrasonic extract. , Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like. In addition, the feed composition or food composition of the present invention may contain flesh for the production of natural fruit juice and fruit juice beverages and vegetable beverages.
본 발명의 유효성분인 효모 초음파 추출물은 화학약품과 같은 부작용이 거의 없이 면역 증강을 목적으로 장기간 복용시에도 안심하고 사용할 수 있다.The ultrasonic yeast extract, an active ingredient of the present invention, has almost no side effects such as chemicals, and can be safely used even when taken for a long time for the purpose of enhancing immunity.
본 발명의 일 실시예에 따르면, 효모 초음파 추출물을 유효 성분으로 함유하는 면역기능강화용 건강기능사료 조성물을 제공할 수 있다. According to an embodiment of the present invention, it is possible to provide a health functional feed composition for strengthening immune function containing an ultrasonic yeast extract as an active ingredient.
한편, 본 발명의 일 실시예에 따르면, 효모 초음파 추출물을 유효 성분으로 함유하는 면역기능강화용 건강기능식품 조성물을 제공할 수 있다. 본 발명의 건강기능식품은 면역 증진을 목적으로, 정제, 캅셀, 분말, 과립, 액상, 환 등의 형태로 제조 및 가공할 수 있다.On the other hand, according to an embodiment of the present invention, it is possible to provide a health functional food composition for strengthening immune function containing an ultrasonic yeast extract as an active ingredient. The health functional food of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. for the purpose of enhancing immunity.
본 발명에서 ‘건강기능식품’이라 함은 건강기능식품에 관한 법률에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 말하며, 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.In the present invention, the term'health functional food' refers to a food manufactured and processed using raw materials or ingredients having useful functions for the human body according to the Health Functional Food Act, and controls nutrients for the structure and function of the human body. It means ingestion for the purpose of obtaining a useful effect for health use such as physiological action.
본 발명의 건강기능식품은 통상의 식품 첨가물을 포함할 수 있으며, 식품 첨가물로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전청에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.The health functional food of the present invention may contain ordinary food additives, and whether it is suitable as a food additive is determined according to the general rules and general test methods for food additives approved by the Food and Drug Administration, unless otherwise specified. It is judged according to standards and standards.
상기 ‘식품 첨가물 공전’에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼슘, 니코틴산, 계피산 등의 화학적 합성물; 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물; L-글루타민산나트륨제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류 등을 들 수 있다.Examples of the items listed in the "Food Additives Code" include chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as reduced pigment, licorice extract, crystalline cellulose, high color pigment, and guar gum; Mixed preparations, such as a sodium L-glutamate preparation, an alkali additive for noodles, a preservative preparation, and a tar color preparation, etc. are mentioned.
예를 들어, 정제 형태의 건강기능식품은 본 발명의 유효성분을 부형제, 결합제, 붕해제 및 다른 첨가제와 혼합한 혼합물을 통상의 방법으로 과립화한 다음, 활택제 등을 넣어 압축성형하거나, 상기 혼합물을 직접 압축 성형할 수 있다. 또한 상기 정제 형태의 건강기능식품은 필요에 따라 교미제 등을 함유할 수도 있다.For example, in the health functional food in the form of a tablet, a mixture obtained by mixing the active ingredient of the present invention with an excipient, a binder, a disintegrant, and other additives is granulated by a conventional method, and then a lubricant, etc. The mixture can be directly compression molded. In addition, the health functional food in the form of a tablet may contain a mating agent or the like, if necessary.
캅셀 형태의 건강기능식품 중 경질 캅셀제는 통상의 경질 캅셀에 본 발명의 유효성분을 충진하여 제조할 수 있으며, 연질 캅셀제는 상기 추출물을 부형제 등의 첨가제와 혼합한 혼합물을 젤라틴과 같은 캅셀기제에 충진하여 제조할 수 있다. 상기 연질 캅셀제는 필요에 따라 글리세린 또는 소르비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다.Among the capsule-type health functional foods, hard capsules can be prepared by filling the active ingredient of the present invention into a conventional hard capsule, and soft capsules are filled with a mixture of the extract and additives such as excipients in a capsule base such as gelatin. It can be manufactured. The soft capsules may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary.
환 형태의 건강기능식품은 본 발명의 유효성분과 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 제피제로 제피할 수 있으며, 또는 전분, 탈크와 같은 물질로 표면을 코팅할 수도 있다.Ring-shaped health functional foods can be prepared by molding a mixture of the active ingredient of the present invention, excipients, binders, disintegrants, etc. by conventionally known methods, and can be coated with white sugar or other coating agents if necessary, Alternatively, the surface may be coated with a material such as starch or talc.
과립 형태의 건강기능식품은 본 발명의 유효성분과 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착향제, 교미제 등을 함유할 수 있다.The health functional food in the form of granules can be prepared in granular form by a mixture of the active ingredient of the present invention, excipients, binders, disintegrants, etc., by a known method, and may contain flavoring agents, flavoring agents, etc. have.
본 발명의 일 실시예에 따르면, 효모 초음파 추출물을 함유하는 약제학적 조성물을 제공할 수 있다. According to an embodiment of the present invention, a pharmaceutical composition containing an ultrasonic yeast extract may be provided.
본 발명의 일 구현예에서, 본 발명의 의약 조성물은 치료용 또는 예방용 의약으로 허용되는 하나 이상의 첨가제를 추가로 함유할 수 있다. 의약으로 허용되는 하나 이상의 첨가제는 특별히 제한되지 않으며 의약 조성물에 배합될 수 있는 통상적인 성분 일 수 있다.In one embodiment of the present invention, the pharmaceutical composition of the present invention may further contain one or more additives that are acceptable as therapeutic or prophylactic drugs. One or more additives that are acceptable as medicines are not particularly limited and may be conventional ingredients that can be blended into a pharmaceutical composition.
본 발명의 구체적인 양태로서의 본 발명의 조성물은 약학 조성물일 수 있다. 상기 본 발명의 조성물이 약학 조성물인 경우 상기 조성물은 약학적으로 허용 가능한 담체를 포함할 수 있다.The composition of the present invention as a specific aspect of the present invention may be a pharmaceutical composition. When the composition of the present invention is a pharmaceutical composition, the composition may include a pharmaceutically acceptable carrier.
약학적으로 허용 가능한 담체를 포함하는 상기 조성물은 경구 또는 비경구의 여러 가지 제형일 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 하나 이상의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제될 수 있다. 또한 단순한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용될 수 있다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함될 수 있다. 비수성용제, 현탁용제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. The composition including a pharmaceutically acceptable carrier may be in various oral or parenteral formulations. In the case of formulation, it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations include at least one excipient in one or more compounds, such as starch, calcium carbonate, sucrose, or lactose ( lactose), gelatin, etc. can be mixed. In addition, in addition to simple excipients, lubricants such as magnesium stearate and talc may be used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups.In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as humectants, sweeteners, fragrances, and preservatives may be included. have. Preparations for parenteral administration may include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used.
상기 약제학적 조성물은 정제, 환제, 산제, 과립제, 캡슐제, 현탁제, 내용액제, 유제, 시럽제, 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제 및 좌제으로 이루어진 군으로부터 선택되는 어느 하나의 제형을 가질 수 있다.The pharmaceutical composition is any selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. It can have one formulation.
상기 본 발명의 조성물은 약학적으로 유효한 양으로 투여할 수 있다. 본 발명에서 용어, "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 개체 종류 및 중증도, 연령, 성별, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다.The composition of the present invention can be administered in a pharmaceutically effective amount. In the present invention, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type and severity of the individual, age, sex, and Activity, sensitivity to drugs, time of administration, route of administration and rate of excretion, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field.
본 발명의 일 구현예에서, 본 발명의 의약 조성물은 주요 성분인 효모 초음파 추출물 이외에, 면역 증강 효과를 상승 또는 보강시킬수 있도록 면역 증강 효과가 있다고 이미 알려졌거나 앞으로 알려질 여타의 공지된 화합물이나 식물 추출물을 함께 포함할 수 있다.In one embodiment of the present invention, the pharmaceutical composition of the present invention contains other known compounds or plant extracts that are known to have an immunity enhancing effect so as to increase or reinforce the immunity enhancing effect, in addition to the yeast ultrasonic extract, which is the main component. Can be included together.
본 발명에서는, 효모 초음파 추출물을 Raw 264.7 세포에 처리한 결과 세포독성 없이 NO 생성량을 증가시키는 것을 최초로 확인하였다. 따라서 본 발명의 효모 초음파 추출물은 면역을 증진시킬 수 있다. In the present invention, it was confirmed for the first time that the amount of NO production was increased without cytotoxicity as a result of treatment of the ultrasonic yeast extract on Raw 264.7 cells. Therefore, the ultrasonic yeast extract of the present invention can enhance immunity.
본 발명의 효모 초음파 추출물의 제조 방법은, a) 효모(Saccharomyces cerevisiae)에 수산화나트륨(NaOH) 수용액을 첨가한 후 초음파를 처리하는 단계; 및 a) 단계를 거친 용액을 중화하는 단계를 포함할 수 있다.The method for preparing the ultrasonic yeast extract of the present invention is a) yeast ( Saccharomyces cerevisiae ) adding an aqueous solution of sodium hydroxide (NaOH), followed by ultrasonic treatment; And it may include a step of neutralizing the solution passed through step a).
a) 단계에서는 효모를 0.1 M 내지 0.5 M의 수산화나트륨 수용액에 침지시키고, 10 ℃ 내지 100 ℃에서 0.5 시간 내지 7 시간 동안 10 kHz 내지 30 kHz의 주파수의 조건으로 초음파 처리할 수 있다. 바람직하게는, 0.25 M 내지 0.5 M의 수산화나트륨 수용액을 이용하여 90 ℃에서 1 시간 내지 5 시간 동안 20 kHz의 주파수의 조건으로 초음파 처리하여 수득될 수 있다. 한편, 80 %의 진폭, 750 W, 펄스(pulse) 20s on/10s off의 조건에서 진행될 수 있다. In step a), the yeast may be immersed in an aqueous solution of 0.1 M to 0.5 M sodium hydroxide, and sonicated at 10° C. to 100° C. for 0.5 to 7 hours at a frequency of 10 kHz to 30 kHz. Preferably, it can be obtained by ultrasonic treatment at 90° C. for 1 hour to 5 hours at a frequency of 20 kHz using an aqueous sodium hydroxide solution of 0.25 M to 0.5 M. On the other hand, it can proceed under the conditions of 80% amplitude, 750 W, and pulse 20s on/10s off.
이후, b) 단계에서는 상기 추출물을 HCl로 중화할 수 있다. 이후, 탈염 및 동결건조가 추가로 이루어질 수도 있다. Thereafter, in step b), the extract may be neutralized with HCl. Thereafter, desalting and freeze-drying may be further performed.
하기의 실시예를 통하여 본 발명을 보다 상세하게 설명한다. 그러나 하기 실시예는 본 발명의 내용을 구체화하기 위한 것일 뿐 실시예에 의해 본 발명이 한정되는 것은 아니다.The present invention will be described in more detail through the following examples. However, the following examples are only for embodiing the contents of the present invention, and the present invention is not limited by the examples.
<실시예-효모 추출물의 제조><Example-Preparation of yeast extract>
효모(Saccharomyces cerevisiae)에 NaOH 수용액(0.1, 0.25, 0.5 M)을 10배량(w/v) 처리하여 시간별(1hr, 3hr, 5hr)로 초음파 추출(20 kHz, 80% ampltude, 750 W, pulse 20 s on/10 s off, 90℃)을 진행하였다. 초음파 추출물의 대조구로서 알칼리 추출물은 효모에 10배량(w/v)의 0.5 M NaOH 수용액을 넣고 90℃에서 5시간 동안 진탕추출하여 제조하였다. 모든 추출물은 HCl로 중화한 후 탈염하여 동결건조하였다. Yeast (Saccharomyces cerevisiae) is treated with 10 times (w/v) NaOH aqueous solution (0.1, 0.25, 0.5 M) and ultrasonically extracted hourly (1hr, 3hr, 5hr) (20 kHz, 80% ampltude, 750 W, pulse 20) s on/10 s off, 90°C). As a control for the ultrasonic extract, the alkaline extract was prepared by adding 10 times (w/v) of 0.5 M NaOH aqueous solution to yeast and extracting with shaking at 90° C. for 5 hours. All extracts were neutralized with HCl, desalted, and lyophilized.
<실험예 1: β-glucan 함량 측정><Experimental Example 1: Measurement of β-glucan content>
β-glucan의 함량 측정은 Megazyme β-glucan assay kit을 사용하여 제공된 protocol에 따라 실시하였다. The content of β-glucan was measured using a Megazyme β-glucan assay kit according to the provided protocol.
그 결과는 하기 표 1과 같다.The results are shown in Table 1 below.
표 1을 참고하면, 초음파 추출 조건에 따라 추출물 중 베타글루칸 함량은 NaOH 농도가 높을수록 증가하는 경향을 나타내었다. 0.25 M, 0.5 M 초음파 추출물은 모든 조건에서 알칼리 5시간 추출물에 비해 높은 베타글루칸 함량이 측정되었다. Referring to Table 1, according to the ultrasonic extraction conditions, the content of beta-glucan in the extract tends to increase as the NaOH concentration increases. The 0.25 M, 0.5 M ultrasonic extract had a higher beta glucan content than the alkaline 5 hour extract under all conditions.
<실험예 2: 효모 추출물의 면역 증진 효능 측정><Experimental Example 2: Measurement of immunity enhancing efficacy of yeast extract>
(1) 세포 배양 (1) cell culture
Abelson 쥐 백혈병 바이러스 유발 종양에서 유래한 macrophage인 Raw 264.7 세포는 10% fetal bovine serum(FBS)와 100 U/mL의 penicillin, 100 mg/mL 의 streptomycin과 10% MEM을 첨가한 DMEM 배양액에서 37℃, 5% CO2에서 배양하였다. 세포를 10cm cell culture plate당 3×105 cells/mL씩 plating 하여 2일 간격으로 계대 배양 하여 실험에 사용하였다. Raw 264.7 cells, macrophages derived from Abelson rat leukemia virus-induced tumors, were prepared in DMEM culture medium containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 mg/mL streptomycin, and 10% MEM at 37°C. Incubated in 5% CO2. Cells were plated at 3×105 cells/mL per 10 cm cell culture plate and subcultured at intervals of 2 days to be used in the experiment.
(2) Nitric Oxide (NO) 생성량 측정(2) Measurement of Nitric Oxide (NO) production
NO의 생성 촉진 효과는 대식세포 활성화의 지표로 대식세포에서 생성되는 NO는 침입한 병원체를 없애고 기본적인 숙주 방어체계를 작동시키는 역할을 한다. 따라서, NO 생성량을 측정함으로써, 면역 증진 효능을 관찰하였다.The effect of promoting the production of NO is an indicator of activation of macrophages, and NO produced in macrophages eliminates invading pathogens and activates the basic host defense system. Therefore, by measuring the amount of NO production, the immunity enhancing efficacy was observed.
Raw 264.7 세포를 계수 후 96 well plate에 1×104 cell/wells로 분주하고 5% CO2, 37℃ 세포 배양기에 24시간 배양하였다. 24시간 후 시료 혹은 LPS(1 μg/mL)를 포함하는 phenol red 무함유 DMEM 배지로 교환하여 다시 24시간 배양하였다. 생성된 NO의 양은 Griess 반응을 이용하여 측정하였다. 상층액 50 μL와 Griess 시약 50 μL(1% sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride, and 5% phosphoric acid)를 혼합하여 10분간 반응시킨 후 microplate reader를 이용하여 540 nm에서 흡광도를 측정하였다. After counting the raw 264.7 cells, the cells were aliquoted into a 96 well plate at 1×104 cells/wells and cultured in a cell incubator at 37°C for 5% CO2 for 24 hours. After 24 hours, the sample or DMEM medium containing no phenol red containing LPS (1 μg/mL) was exchanged and cultured again for 24 hours. The amount of NO produced was measured using the Griess reaction. 50 μL of the supernatant and 50 μL of Griess reagent (1% sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride, and 5% phosphoric acid) were mixed and reacted for 10 minutes, and the absorbance was measured at 540 nm using a microplate reader.
(3) MTS 방법에 의한 세포 독성 측정 (3) Measurement of cytotoxicity by MTS method
각 시료의 처리 조건에서의 세포 독성을 확인하기 위하여, Raw 264.7 세포를 1×103 cells/well이 되도록 조절하여 96 well plate에서 24시간 동안 배양하였다. 이후 시료를 혼합한 phenol red 무함유 DMEM 배지로 교환하여 다시 24시간 배양 후 세포독성을 MTS 방법으로 측정하였다. 2.0 mL의 MTS 용액과 100 μL의 PMS(phenazine methosulfate) 용액의 혼합액을 배양액에 20 μL 씩 넣고 37℃, 5% CO2 배양기에서 1시간 반응시킨 후 microplate reader로 반응 생성물인 formazan의 흡광도를 490 nm에서 측정하였다.In order to confirm the cytotoxicity under the treatment conditions of each sample, Raw 264.7 cells were adjusted to 1×10 3 cells/well and cultured in a 96 well plate for 24 hours. Thereafter, the sample was exchanged with the mixed phenol red-free DMEM medium and cultured again for 24 hours, and then cytotoxicity was measured by the MTS method. Add 20 μL of a mixture of 2.0 mL of MTS solution and 100 μL of PMS (phenazine methosulfate) solution to the culture medium and react for 1 hour in a 5% CO2 incubator at 37°C. Measured.
도 1을 참고하면, 세포에 처리한 추출물 농도를 각각 200 ug/ml, 400 ug/ml 로 하여 NO 생성량을 측정하였다. 그 결과, 초음파 추출물은 거의 모든 조건에서 대조구인 알칼리 추출물에 비해 향상된 면역 증진 효능을 보였다. 그 중에서도 0.25 M NaOH를 사용한 그룹(시료번호 4, 5 및 6)에서 효능이 가장 높게 나타났으며, 상대적으로 베타글루칸이 적게 검출된 0.1 M NaOH 그룹(시료번호 1, 2 및 3)에서는 효능이 낮게 관찰되었다. 즉, 베타글루칸을 6 % 내지 11 % 함유하는 효모 초음파 추출물의 면역 증진 효능이 높은 것으로 나타났다. 한편, 본 발명의 실시예인 시료번호 1 내지 9 모두 대조군인 베타글루칸보다도 면역 증진 효능이 높은 것으로 관찰되었다. Referring to FIG. 1, the concentration of the extract treated on the cells was 200 ug/ml and 400 ug/ml, respectively, and the amount of NO production was measured. As a result, the ultrasonic extract showed improved immunity enhancing efficacy compared to the control alkali extract under almost all conditions. Among them, the efficacy was the highest in the group using 0.25 M NaOH (Sample Nos. 4, 5 and 6), and the efficacy was relatively low in the 0.1 M NaOH group (Sample Nos. 1, 2 and 3) in which beta-glucan was detected. Observed low. That is, it was found that the immunity enhancing efficacy of the ultrasonic yeast extract containing 6% to 11% beta-glucan was high. On the other hand, it was observed that both samples Nos. 1 to 9, which are examples of the present invention, have higher immunity enhancing efficacy than beta-glucan, a control group.
도 2를 참고하면, 실험에 사용한 모든 처리 조건에서 추출물은 세포 독성은 보이지 않음을 확인하였다. Referring to FIG. 2, it was confirmed that the extract did not show cytotoxicity under all treatment conditions used in the experiment.
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특허청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.So far, the present invention has been looked at around its preferred embodiments. Those of ordinary skill in the art to which the present invention pertains will be able to understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an illustrative point of view rather than a limiting point of view. The scope of the present invention is shown in the claims rather than the above description, and all differences within the scope equivalent thereto should be construed as being included in the present invention.
Claims (10)
상기 효모 초음파 추출물은 수산화나트륨(NaOH) 수용액을 용매로 이용하여 수득된 것을 특징으로 하는 면역기능강화용 사료 조성물.The method of claim 1,
The yeast ultrasonic extract is a feed composition for enhancing immune function, characterized in that obtained by using an aqueous sodium hydroxide (NaOH) solution as a solvent.
상기 효모 초음파 추출물은 0.1 M 내지 0.5 M의 수산화나트륨 수용액을 이용하여 10 ℃ 내지 100 ℃에서 0.5 시간 내지 7 시간 동안 10 kHz 내지 30 kHz의 주파수의 조건으로 초음파 처리하여 수득한 것을 특징으로 하는 면역기능강화용 사료 조성물.The method of claim 1,
The yeast ultrasonic extract is obtained by ultrasonic treatment at a frequency of 10 kHz to 30 kHz at 10° C. to 100° C. for 0.5 to 7 hours using 0.1 M to 0.5 M sodium hydroxide aqueous solution. Fortified feed composition.
상기 효모 초음파 추출물은 1 % 내지 20 %의 베타글루칸(β-glucan)을 함유하는 것을 특징으로 하는 면역기능강화용 사료 조성물.The method of claim 1,
The yeast ultrasonic extract is a feed composition for enhancing immune function, characterized in that it contains 1% to 20% of beta-glucan (β-glucan).
상기 효모 초음파 추출물은 0.1 M 내지 0.5 M의 수산화나트륨 수용액을 이용하여 10 ℃ 내지 100 ℃에서 0.5 시간 내지 7 시간 동안 10 kHz 내지 30 kHz의 주파수의 조건으로 초음파 처리하여 수득한 것을 특징으로 하는 면역기능강화용 식품 조성물.The method of claim 5,
The yeast ultrasonic extract is obtained by ultrasonic treatment at a frequency of 10 kHz to 30 kHz at 10° C. to 100° C. for 0.5 to 7 hours using 0.1 M to 0.5 M sodium hydroxide aqueous solution. Food composition for fortification.
상기 효모 초음파 추출물은 1 % 내지 20 %의 베타글루칸(β-glucan)을 함유하는 것을 특징으로 하는 면역기능강화용 식품 조성물.The method of claim 5,
The yeast ultrasonic extract is a food composition for enhancing immune function, characterized in that it contains 1% to 20% of beta-glucan (β-glucan).
상기 식품은 음료류, 육류, 초코렛, 식품류, 과자류, 피자, 라면, 기타 면류, 껌류, 사탕류, 아이스크림류, 알코올 음료류, 비타민 복합제 및 건강보조식품류로 이루어진 군으로부터 선택되는 것을 특징으로 하는 면역기능강화용 식품 조성물.The method of claim 5,
The food is selected from the group consisting of beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplements. Food composition.
b) 상기 a) 단계를 거친 용액을 중화하는 단계를 포함하는 효모 초음파 추출물의 제조 방법.a) yeast ( Saccharomyces cerevisiae ) adding an aqueous sodium hydroxide (NaOH) solution and then performing ultrasonic treatment; And
b) A method for producing an ultrasonic yeast extract comprising the step of neutralizing the solution passed through the step a).
상기 a) 단계는 효모를 0.1 M 내지 0.5 M의 수산화나트륨 수용액에 침지시키고, 10 ℃ 내지 100 ℃에서 0.5 시간 내지 7 시간 동안 10 kHz 내지 30 kHz의 주파수의 조건으로 초음파 처리하는 것을 특징으로 하는 효모 초음파 추출물의 제조 방법. The method of claim 9,
The step a) is yeast, characterized in that the yeast is immersed in an aqueous solution of 0.1 M to 0.5 M sodium hydroxide, and sonicated at a frequency of 10 kHz to 30 kHz at 10° C. to 100° C. for 0.5 to 7 hours. Method of making an ultrasonic extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190056423A KR20200131603A (en) | 2019-05-14 | 2019-05-14 | Feed composition for immunity comprising extract from yeast, food composition for immunity comprising extract from yeast and manufactuaring method for extract from yeast using ultrasonics wave |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190056423A KR20200131603A (en) | 2019-05-14 | 2019-05-14 | Feed composition for immunity comprising extract from yeast, food composition for immunity comprising extract from yeast and manufactuaring method for extract from yeast using ultrasonics wave |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200131603A true KR20200131603A (en) | 2020-11-24 |
Family
ID=73679585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190056423A KR20200131603A (en) | 2019-05-14 | 2019-05-14 | Feed composition for immunity comprising extract from yeast, food composition for immunity comprising extract from yeast and manufactuaring method for extract from yeast using ultrasonics wave |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20200131603A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220109648A (en) * | 2021-01-29 | 2022-08-05 | 이상만 | Method for producing beta-glucan-containing protein chocolate balls |
-
2019
- 2019-05-14 KR KR1020190056423A patent/KR20200131603A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220109648A (en) * | 2021-01-29 | 2022-08-05 | 이상만 | Method for producing beta-glucan-containing protein chocolate balls |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5296436B2 (en) | Method for producing low molecular weight beta glucan by irradiation with radiation and low molecular weight beta glucan produced by irradiation with radiation | |
| US10639320B2 (en) | Pharmaceutical composition comprising gold-containing agent for preventing or treating liver fibrosis or liver cirrhosis | |
| JP2020506683A (en) | A composition for enhancing immunity containing ginseng berry polysaccharide | |
| US11413333B2 (en) | Composition containing inducer of SIRT1 expression for preventing or treating sepsis or septic shock | |
| KR101614574B1 (en) | Composition of Diabetes-Improving Effective Constituents by Fermentation Products of the Trifoliate Orange | |
| US20190076496A1 (en) | Polysaccharide digestion inhibitor | |
| KR101045031B1 (en) | A composition comprising fruits of Cudrania tricuspidata for immunopotentiating | |
| KR20060009391A (en) | Extract from plant of japanese parsley family and process for producing the same | |
| KR101379427B1 (en) | Composition for preventing or treating renal fibrosis comprising dimethylfumarate | |
| KR101915715B1 (en) | Polysaccharide fraction isolated from by-product of carrot with immune-enhancing activity and method for producing the same | |
| KR20200131603A (en) | Feed composition for immunity comprising extract from yeast, food composition for immunity comprising extract from yeast and manufactuaring method for extract from yeast using ultrasonics wave | |
| KR101620275B1 (en) | Brown algae-derived mixed composition and preparation method thereof | |
| KR101659927B1 (en) | Enhancing method for pharmaceutical effect of herb, preparation method for fermented chitosan for immune stimulating and its use | |
| KR101534498B1 (en) | Composition comprising the extract of Ceramium boydenii for preventing and treating inflammatory diseases | |
| JP2004269422A (en) | Immunoactivating composition | |
| KR101767837B1 (en) | Method for producing mixture extract of sea cucumber and sea mustard with enhanced immunity activity | |
| KR101905009B1 (en) | Polysaccharide fraction isolated from kale with immune-enhancing activity and method for producing the same | |
| KR101839186B1 (en) | Use of Aplysia kurodai extract having retinal cell regeneration effect | |
| KR20200085070A (en) | Composition for preventing, improving or treating cachexia comprising natural product as effective component | |
| KR102480734B1 (en) | Antioxidant, anti-inflammatory or antibacterial composition comprising fermented aloe and kelp or extracts thereof | |
| EP3960189A1 (en) | Antiviral composition having antiviral activity against coronavirus and variant viruses thereof | |
| KR101140683B1 (en) | A method for producing the low molecular weight beta-glucan by irradiation and low molecular weight beta-glucan produced by the method | |
| JP7045661B2 (en) | Immunostimulatory composition and immunostimulatory food composition | |
| KR102001557B1 (en) | Composition for preventing or treating metabolic disease comprising Artemisiae capillaris herba and Citrus unshiu peel complex extract as an active ingredient | |
| KR102133218B1 (en) | Composition comprising fat reduction aid andbetaglucan as an effective ingredient for preventing or treating of obesity |